Psychiatric and medical comorbidities, associated pain, and health care utilization of patients prescribed buprenorphine
Psychiatric and medical comorbidities, associated pain, and health care utilization of patients prescribed buprenorphine
复制标题
DOI：
10.1016/j.jsat.2012.11.004
复制
发表时间：
2013-05-01
影响因子：
3.9
通讯作者：
Miller, Kay
中科院分区：
文献类型：
--
作者：
Mark, Tami L.;Dilonardo, Joan;Miller, Kay
本研究使用2007-2009年MarketScan研究数据库描述了接受丁丙诺啡治疗的个体的合并症和医疗保健利用。丁丙诺啡接受者患有与慢性疼痛相关的合并症的患病率很高，包括背部问题（42%），结缔组织疾病（24-27%）和非创伤性关节疾病（20-23%）。大约69%的接受者在开始丁丙诺啡治疗前6个月内填写了阿片类激动剂药物处方。丁丙诺啡接受者经常被诊断为焦虑（23-42%）和情绪障碍（39-51%），并以高比例填写抗抑郁药（47-56%）和苯二氮卓类药物（47-56%）的处方。令人惊讶的是，只有53-54%的丁丙诺啡处方患者有编码的阿片类药物滥用/依赖诊断。需要研究以更好地了解丁丙诺啡在处方药滥用背景下的有效性，以及协调服务以解决患者共病成瘾，疼痛和精神疾病的最佳方式。(C)2013 Elsevier Inc. All rights reserved.
This study describes the comorbidities and health care utilization of individuals treated with buprenorphine using the 2007-2009 MarketScan Research Databases. Buprenorphine recipients had a high prevalence of comorbidities associated with chronic pain, including back problems (42%), connective tissue disease (24-27%), and nontraumatic joint disorders (20-23%). Approximately 69% of recipients filled prescriptions for opioid agonist medications in the 6 months before buprenorphine initiation. Buprenorphine recipients were frequently diagnosed with anxiety (23-42%) and mood disorders (39-51%) and filled prescriptions for antidepressants (47-56%) and benzodiazepines (47-56%) at high rates. Surprisingly, only 53-54% of patients filling a prescription for buprenorphine had a coded opioid abuse/dependence diagnosis. Research is needed to better understand buprenorphine's effectiveness in the context of prescription drug abuse and the best way to coordinate services to address the patient's comorbid addiction, pain, and psychiatric illnesses. (C) 2013 Elsevier Inc. All rights reserved.